{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:13:00Z","timestamp":1774480380482,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cheminform"],"DOI":"10.1186\/s13321-025-00962-0","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:05:19Z","timestamp":1738670719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Improving drug repositioning with negative data labeling using large language models"],"prefix":"10.1186","volume":"17","author":[{"given":"Milan","family":"Picard","sequence":"first","affiliation":[]},{"given":"Mickael","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Antoine","family":"Bodein","sequence":"additional","affiliation":[]},{"given":"Marie Pier","family":"Scott-Boyer","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Perin","sequence":"additional","affiliation":[]},{"given":"Arnaud","family":"Droit","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"962_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.11.014","author":"RA Roberts","year":"2014","unstructured":"Roberts RA et al (2014) Reducing attrition in drug development: smart loading preclinical safety assessment. Drug Discovery Today. https:\/\/doi.org\/10.1016\/j.drudis.2013.11.014","journal-title":"Drug Discovery Today"},{"key":"962_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.003","author":"V Palve","year":"2021","unstructured":"Palve V, Liao Y, Remsing Rix LL, Rix U (2021) Turning liabilities into opportunities: off-target based drug repurposing in cancer. Seminars Cancer Biol. https:\/\/doi.org\/10.1016\/j.semcancer.2020.02.003","journal-title":"Seminars Cancer Biol"},{"key":"962_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00500","author":"B Turanli","year":"2018","unstructured":"Turanli B et al (2018) Drug repositioning for effective prostate cancer treatment. Front Physiol. https:\/\/doi.org\/10.3389\/fphys.2018.00500","journal-title":"Front Physiol"},{"key":"962_CR4","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2017.0127","author":"B Turanli","year":"2017","unstructured":"Turanli B, Gulfidan G, Arga KY (2017) Transcriptomic-guided drug repositioning supported by a new bioinformatics search tool: genexpharma. OMICS. https:\/\/doi.org\/10.1089\/omi.2017.0127","journal-title":"OMICS."},{"key":"962_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.037","author":"KM Gayvert","year":"2016","unstructured":"Gayvert KM et al (2016) A computational drug repositioning approach for targeting oncogenic transcription factors. Cell Rep. https:\/\/doi.org\/10.1016\/j.celrep.2016.05.037","journal-title":"Cell Rep"},{"key":"962_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.crchbi.2023.100042","author":"L Cai","year":"2023","unstructured":"Cai L et al (2023) Machine learning for drug repositioning: recent advances and challenges. Current Res Chem Biol. https:\/\/doi.org\/10.1016\/j.crchbi.2023.100042","journal-title":"Current Res Chem Biol"},{"key":"962_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-3263-","author":"S Hu","year":"2019","unstructured":"Hu S et al (2019) Predicting drug-target interactions from drug structure and protein sequence using novel convolutional neural networks. BMC Bioinform. https:\/\/doi.org\/10.1186\/s12859-019-3263-","journal-title":"BMC Bioinform"},{"key":"962_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1008040","author":"H Chen","year":"2020","unstructured":"Chen H, Cheng F, Li J (2020) IDrug: Integration of drug repositioning and drug-target prediction via cross-network embedding. PLoS Comput Biol. https:\/\/doi.org\/10.1371\/journal.pcbi.1008040","journal-title":"PLoS Comput Biol"},{"key":"962_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020.e03444","author":"F Rayhan","year":"2020","unstructured":"Rayhan F, Ahmed S, Mousavian Z, Farid DM, Shatabda S (2020) FRnet-DTI: deep convolutional neural network for drug-target interaction prediction. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2020.e03444","journal-title":"Heliyon"},{"key":"962_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty417","author":"RS Olayan","year":"2018","unstructured":"Olayan RS, Ashoor H, Bajic VB (2018) DDR: efficient computational method to predict drug-target interactions using graph mining and machine learning approaches. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/bty417","journal-title":"Bioinformatics"},{"key":"962_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab581","author":"Y Meng","year":"2022","unstructured":"Meng Y et al (2022) A weighted bilinear neural collaborative filtering approach for drug repositioning. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbab581","journal-title":"Brief Bioinform"},{"key":"962_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/genes12010025","author":"HG Chen","year":"2021","unstructured":"Chen HG, Zhou XH (2021) Mnbdr: a module network based method for drug repositioning. Genes. https:\/\/doi.org\/10.3390\/genes12010025","journal-title":"Genes"},{"key":"962_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00924","author":"Z Li","year":"2020","unstructured":"Li Z et al (2020) Identification of drug-disease associations using information of molecular structures and clinical symptoms via deep convolutional neural network. Front Chem. https:\/\/doi.org\/10.3389\/fchem.2019.00924","journal-title":"Front Chem"},{"key":"962_CR14","first-page":"2739","volume":"380","author":"X Lin","year":"2021","unstructured":"Lin X, Quan Z, Wang ZJ, Ma T, Zeng XKGNN (2021) Knowledge graph neural network for drug-drug interaction prediction. IJCAI Int Joint Conf Artif Intell 380:2739","journal-title":"IJCAI Int Joint Conf Artif Intell"},{"key":"962_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/app10155076","author":"Y Ko","year":"2020","unstructured":"Ko Y (2020) Computational drug repositioning: current progress and challenges. Appl Sci. https:\/\/doi.org\/10.3390\/app10155076","journal-title":"Appl Sci"},{"key":"962_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.08.002","author":"J Schuler","year":"2022","unstructured":"Schuler J et al (2022) Evaluating the performance of drug-repurposing technologies. Drug Disc Today. https:\/\/doi.org\/10.1016\/j.drudis.2021.08.002","journal-title":"Drug Disc Today"},{"key":"962_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s10994-020-05877-5","author":"J Bekker","year":"2020","unstructured":"Bekker J, Davis J (2020) Learning from positive and unlabeled data: a survey. Mach Learn. https:\/\/doi.org\/10.1007\/s10994-020-05877-5","journal-title":"Mach Learn"},{"key":"962_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz418","author":"X Zeng","year":"2019","unstructured":"Zeng X et al (2019) DeepDR: a network-based deep learning approach to in silico drug repositioning. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/btz418","journal-title":"Bioinformatics"},{"key":"962_CR19","doi-asserted-by":"publisher","DOI":"10.4038\/icter.v15i3.7232","author":"YR Maralanda","year":"2022","unstructured":"Maralanda YR, Hameed PN (2022) Improving drug combination repositioning using positive unlabelled learning and ensemble learning. Int J Adv ICT Emerg Regions (ICTer). https:\/\/doi.org\/10.4038\/icter.v15i3.7232","journal-title":"Int J Adv ICT Emerg Regions (ICTer)."},{"key":"962_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neucom.2016.03.080","author":"W Lan","year":"2016","unstructured":"Lan W et al (2016) Predicting drug\u2013target interaction using positive-unlabeled learning. Neurocomputing. https:\/\/doi.org\/10.1016\/j.neucom.2016.03.080","journal-title":"Neurocomputing"},{"key":"962_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-3214-6","author":"Y Zheng","year":"2019","unstructured":"Zheng Y et al (2019) DDI-PULearn: a positive-unlabeled learning method for large-scale prediction of drug-drug interactions. BMC Bioinform. https:\/\/doi.org\/10.1186\/s12859-019-3214-6","journal-title":"BMC Bioinform"},{"key":"962_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.872785","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lei X, Pan Y, Wu FX (2022) Drug repositioning with GraphSAGE and clustering constraints based on drug and disease networks. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.872785","journal-title":"Front Pharmacol"},{"key":"962_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biom12101497","author":"Y Kim","year":"2022","unstructured":"Kim Y, Jung YS, Park JH, Kim SJ, Cho YR (2022) Drug-disease association prediction using heterogeneous networks for computational drug repositioning. Biomolecules. https:\/\/doi.org\/10.3390\/biom12101497","journal-title":"Biomolecules"},{"key":"962_CR24","volume-title":"Machine learning and other soft computing techniques: biomedical and related applications","author":"H Le Manh","year":"2024","unstructured":"Le Manh H, Dao NA (2024) Machine learning and other soft computing techniques: biomedical and related applications. Springer Nature Switzerland, Cham"},{"key":"962_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08079-7","author":"L Peng","year":"2017","unstructured":"Peng L et al (2017) Screening drug-target interactions with positive-unlabeled learning. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-017-08079-7","journal-title":"Sci Rep"},{"key":"962_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ph11020057","author":"JK Yella","year":"2018","unstructured":"Yella JK, Yaddanapudi S, Wang Y, Jegga AG (2018) Changing trends in computational drug repositioning. Pharmaceuticals. https:\/\/doi.org\/10.3390\/ph11020057","journal-title":"Pharmaceuticals"},{"key":"962_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.29","author":"AS Brown","year":"2017","unstructured":"Brown AS, Patel CJ (2017) A standard database for drug repositioning. Sci Data. https:\/\/doi.org\/10.1038\/sdata.2017.29","journal-title":"Sci Data"},{"key":"962_CR28","doi-asserted-by":"publisher","first-page":"bbae328","DOI":"10.1093\/bib\/bbae328","volume":"25","author":"A Ianevski","year":"2024","unstructured":"Ianevski A et al (2024) RepurposeDrugs: an interactive web-portal and predictive platform for repurposing mono\u2014and combination therapies. Brief Bioinform 25:bbae328","journal-title":"Brief Bioinform"},{"key":"962_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2016.6008","author":"TJ Hwang","year":"2016","unstructured":"Hwang TJ et al (2016) Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. https:\/\/doi.org\/10.1001\/jamainternmed.2016.6008","journal-title":"JAMA Intern Med"},{"key":"962_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-1870-2","author":"C Heneghan","year":"2017","unstructured":"Heneghan C, Goldacre B, Mahtani KR (2017) Why clinical trial outcomes fail to translate into benefits for patients. Trials. https:\/\/doi.org\/10.1186\/s13063-017-1870-2","journal-title":"Trials"},{"key":"962_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1284","author":"D Pasalic","year":"2020","unstructured":"Pasalic D et al (2020) Association of industry sponsorship with cancer clinical trial accrual. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1284","journal-title":"JAMA Oncol"},{"key":"962_CR32","doi-asserted-by":"publisher","first-page":"33677","DOI":"10.1371\/journal.pone.0033677","volume":"7","author":"A Tasneem","year":"2012","unstructured":"Tasneem A et al (2012) The database for aggregate analysis of Clinicaltrial.gov and subsequent regrouping by clinical specialty. PLoS ONE 7:33677","journal-title":"PLoS ONE"},{"key":"962_CR33","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a030361","author":"CH Pernar","year":"2018","unstructured":"Pernar CH, Ebot EM, Wilson KM, Mucci LA (2018) The epidemiology of. Prostate Cancer. https:\/\/doi.org\/10.1101\/cshperspect.a030361","journal-title":"Prostate Cancer"},{"key":"962_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/medsci10010015","author":"HF Bahmad","year":"2022","unstructured":"Bahmad HF et al (2022) Overcoming drug resistance in advanced prostate cancer by drug repurposing. Med Sci. https:\/\/doi.org\/10.3390\/medsci10010015","journal-title":"Med Sci"},{"key":"962_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092426","author":"GS Netti","year":"2021","unstructured":"Netti GS et al (2021) Role of complement in regulating inflammation processes in renal and prostate cancers. Cells. https:\/\/doi.org\/10.3390\/cells10092426","journal-title":"Cells"},{"key":"962_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75376-z","author":"G Stallone","year":"2020","unstructured":"Stallone G et al (2020) Modulation of complement activation by pentraxin-3 in prostate cancer. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-020-75376-z","journal-title":"Sci Rep"},{"key":"962_CR37","doi-asserted-by":"publisher","DOI":"10.20157\/cdr.2021.150","author":"N Hussain","year":"2022","unstructured":"Hussain N et al (2022) Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach. Cancer Drug Resistance. https:\/\/doi.org\/10.20157\/cdr.2021.150","journal-title":"Cancer Drug Resistance"},{"key":"962_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231221337","author":"MT Bourlon","year":"2024","unstructured":"Bourlon MT, Valdez P, Castro E (2024) Development of PARP inhibitors in advanced prostate cancer. Ther Adv Med Oncol. https:\/\/doi.org\/10.1177\/17588359231221337","journal-title":"Ther Adv Med Oncol"},{"key":"962_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23446","author":"H Bonkhoff","year":"2018","unstructured":"Bonkhoff H (2018) Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. Prostate. https:\/\/doi.org\/10.1002\/pros.23446","journal-title":"Prostate"},{"key":"962_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.811578","author":"A Ram\u00edrez-de-Arellano","year":"2022","unstructured":"Ram\u00edrez-de-Arellano A et al (2022) Distribution and effects of estrogen receptors in prostate cancer: associated molecular mechanisms. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2021.811578","journal-title":"Front Endocrinol"},{"key":"962_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2001936","author":"S Li","year":"2022","unstructured":"Li S, Cao L (2022) Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. https:\/\/doi.org\/10.1080\/21655979.2021.2001936","journal-title":"Bioengineered"},{"key":"962_CR42","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1574","author":"S Hafiz","year":"2012","unstructured":"Hafiz S et al (2012) Expression of melanocortin receptors in human prostate cancer cell lines: MC2R activation by ACTH increases prostate cancer cell proliferation. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2012.1574","journal-title":"Int J Oncol"},{"key":"962_CR43","doi-asserted-by":"publisher","DOI":"10.2337\/db13-1169","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T et al (2014) Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. https:\/\/doi.org\/10.2337\/db13-1169","journal-title":"Diabetes"},{"key":"962_CR44","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1825","author":"MA Nauck","year":"2018","unstructured":"Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB (2018) Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care. https:\/\/doi.org\/10.2337\/dc17-1825","journal-title":"Diabetes Care"},{"key":"962_CR45","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S153780","author":"MS Al-Keilani","year":"2018","unstructured":"Al-Keilani MS, Alsmadi DH, Darweesh RS, Alzoubi KH (2018) Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy. Clin Pharmacol. https:\/\/doi.org\/10.2147\/CPAA.S153780","journal-title":"Clin Pharmacol"},{"key":"962_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s44254-023-00049-9","author":"X Wang","year":"2024","unstructured":"Wang X, Tao Y, Zhang C, Tian J, Yu W (2024) Expression heterogeneity, tumor immune characteristics and the prognosis effects of OPRL1 in patients with tumors: a pan-cancer study combined with bioinformation analyses and in vitro validation. Anesthesiol Perioperative Sci. https:\/\/doi.org\/10.1007\/s44254-023-00049-9","journal-title":"Anesthesiol Perioperative Sci"},{"key":"962_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4523","author":"E Stikbakke","year":"2011","unstructured":"Stikbakke E et al (2011) Systolic and diastolic blood pressure, prostate cancer risk, treatment, and survival the PROCA-life study. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.4523","journal-title":"Cancer Med"},{"key":"962_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00437-1","author":"VS Chelakkot","year":"2023","unstructured":"Chelakkot VS et al (2023) MC1R signaling through the cAMP-CREB\/ATF-1 and ERK-NF\u03baB pathways accelerates G1\/S transition promoting breast cancer progression. NPJ Precis Oncol. https:\/\/doi.org\/10.1038\/s41698-023-00437-1","journal-title":"NPJ Precis Oncol"},{"key":"962_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112546","volume":"138","author":"S Zhu","year":"2024","unstructured":"Zhu S et al (2024) MC1R regulates T regulatory cell differentiation through metabolic reprogramming to promote colon cancer. Int Immunopharmacol 138:112546","journal-title":"Int Immunopharmacol"},{"key":"962_CR50","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","volume":"27","author":"MJ Schlumberger","year":"2009","unstructured":"Schlumberger MJ et al (2009) Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794","journal-title":"J Clin Oncol"},{"key":"962_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2694-y","author":"N Tebbutt","year":"2015","unstructured":"Tebbutt N et al (2015) Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-015-2694-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"962_CR52","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1155","author":"A Coxon","year":"2009","unstructured":"Coxon A et al (2009) Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth Factor, and kit receptors. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1155","journal-title":"Clin Cancer Res"},{"key":"962_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa993","author":"TK Sheils","year":"2021","unstructured":"Sheils TK et al (2021) TCRD and pharos 2021: mining the human proteome for disease biology. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaa993","journal-title":"Nucleic Acids Res"},{"key":"962_CR54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03730.x","author":"W Koechling","year":"2021","unstructured":"Koechling W, Hjortkjaer R, Tank\u00f3Degarelix LB (2021) a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03730.x","journal-title":"Br J Clin Pharmacol"},{"key":"962_CR55","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/pros.24674","volume":"84","author":"A Ulys","year":"2024","unstructured":"Ulys A et al (2024) Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: a multicenter, open-label, phase 2 trial. Prostate 84:598","journal-title":"Prostate"},{"key":"962_CR56","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa989","author":"SG Creemers","year":"2021","unstructured":"Creemers SG et al (2021) Levoketoconazole, the 2S,4R enantiomer of ketoconazole, a new steroidogenesis inhibitor for Cushing\u2019s syndrome treatment. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa989","journal-title":"J Clin Endocrinol Metab"},{"key":"962_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22936","author":"A Chimento","year":"2012","unstructured":"Chimento A et al (2012) Nandrolone and stanozolol induce leydig cell tumor proliferation through an estrogen-dependent mechanism involving IGF-I system. J Cell Physiol. https:\/\/doi.org\/10.1002\/jcp.22936","journal-title":"J Cell Physiol"},{"key":"962_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2012.08.002","author":"R Sirianni","year":"2012","unstructured":"Sirianni R et al (2012) Nandrolone and stanozolol upregulate aromatase expression and further increase IGF-I-dependent effects on MCF-7 breast cancer cell proliferation. Mol Cell Endocrinol. https:\/\/doi.org\/10.1016\/j.mce.2012.08.002","journal-title":"Mol Cell Endocrinol"},{"key":"962_CR59","doi-asserted-by":"publisher","DOI":"10.1109\/TCBB.2018.2832078","author":"H Luo","year":"2019","unstructured":"Luo H et al (2019) Computational drug repositioning with random walk on a heterogeneous network. IEEE\/ACM Trans Comput Biol Bioinform. https:\/\/doi.org\/10.1109\/TCBB.2018.2832078","journal-title":"IEEE\/ACM Trans Comput Biol Bioinform"},{"key":"962_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0910-y","author":"X Feng","year":"2020","unstructured":"Feng X et al (2020) The association of diabetes with risk of prostate cancer defined by clinical and molecular features. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-020-0910-y","journal-title":"Br J Cancer"},{"key":"962_CR61","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.3390\/jcm11226762","volume":"11","author":"SZ Lutz","year":"2022","unstructured":"Lutz SZ et al (2022) Diabetes and the prostate: elevated fasting glucose, insulin resistance and higher levels of adrenal steroids in prostate cancer. J Clin Med 11:6762","journal-title":"J Clin Med"},{"key":"962_CR62","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkab023","author":"S Kelkar","year":"2021","unstructured":"Kelkar S et al (2021) Diabetes and prostate cancer outcomes in obese and nonobese men after radical prostatectomy. JNCI Cancer Spectr. https:\/\/doi.org\/10.1093\/jncics\/pkab023","journal-title":"JNCI Cancer Spectr"},{"key":"962_CR63","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030191","author":"N Tzenios","year":"2022","unstructured":"Tzenios N, Tazanios ME, Chahine M (2022) The impact of body mass index on prostate cancer: an updated systematic review and meta-analysis. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000030191","journal-title":"Medicine"},{"key":"962_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-023-00764-9","author":"A Saha","year":"2023","unstructured":"Saha A, Kolonin MG, DiGiovanni J (2023) Obesity and prostate cancer\u2014microenvironmental roles of adipose tissue. Nature Rev Urol. https:\/\/doi.org\/10.1038\/s41585-023-00764-9","journal-title":"Nature Rev Urol"},{"key":"962_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12309","author":"A Tenuta","year":"2014","unstructured":"Tenuta A, Klotz L, Parker JL (2014) Clinical trial risk in castration-resistant prostate cancer: Immunotherapies show promise. BJU Int. https:\/\/doi.org\/10.1111\/bju.12309","journal-title":"BJU Int"},{"key":"962_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.028","author":"P Nuhn","year":"2019","unstructured":"Nuhn P et al (2019) Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2018.03.028","journal-title":"Eur Urol"},{"key":"962_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.120","author":"TA Yap","year":"2016","unstructured":"Yap TA et al (2016) Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Rev Drug Disc. https:\/\/doi.org\/10.1038\/nrd.2016.120","journal-title":"Nature Rev Drug Disc"},{"key":"962_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037","author":"DS Wishart","year":"2018","unstructured":"Wishart DS et al (2018) DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"962_CR69","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn307","author":"Y Cao","year":"2008","unstructured":"Cao Y, Charisi A, Cheng LC, Jiang T, Girke TCR (2008) A compound mining framework for R. Bioinformatics. https:\/\/doi.org\/10.1093\/bioinformatics\/btn307","journal-title":"Bioinformatics"},{"key":"962_CR70","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/nar\/gkq1018","volume":"39","author":"D Croft","year":"2011","unstructured":"Croft D et al (2011) Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res 39:691","journal-title":"Nucleic Acids Res"},{"key":"962_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-13-20","author":"G Sales","year":"2012","unstructured":"Sales G, Calura E, Cavalieri D, Romualdi C (2012) Graphite\u2014a bioconductor package to convert pathway topology to gene network. BMC Bioinform. https:\/\/doi.org\/10.1186\/1471-2105-13-20","journal-title":"BMC Bioinform"},{"key":"962_CR72","unstructured":"Grote, S. (2022) Title Gene ontology enrichment using FUNC. R package version 1.18.0 R package."},{"key":"962_CR73","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.csbj.2024.06.012","volume":"24","author":"M Picard","year":"2024","unstructured":"Picard M et al (2024) Target repositioning using multi-layer networks and machine learning: The case of prostate cancer. Comput Struct Biotechnol J 24:464\u2013475","journal-title":"Comput Struct Biotechnol J"},{"key":"962_CR74","doi-asserted-by":"crossref","unstructured":"Li, R., Zhu, J., Zhong, W.-D. & Jia, Z. (2022) PCaDB\u2014a comprehensive and interactive database for transcriptomes from prostate cancer population cohorts. bioRxiv.","DOI":"10.1101\/2021.06.29.449134"},{"key":"962_CR75","unstructured":"Meyer, D. et al. (2022). e1071: Misc functions of the department of statistics, probability theory group (Formerly: E1071), TU Wien. R package version 1.7\u201312 Preprint at."},{"key":"962_CR76","doi-asserted-by":"crossref","unstructured":"Liaw, A. & Wiener, M. (2002). Classification and Regression by randomForest. R News 2.","DOI":"10.1057\/9780230509993"},{"key":"962_CR77","unstructured":"LeDell, E. et al. (2020) R Interface for the \u2018H2O\u2019 Scalable Machine Learning Platform."},{"key":"962_CR78","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v033.i01","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R (2010) Regularization paths for generalized linear models via coordinate descent. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v033.i01","journal-title":"J Stat Softw"},{"key":"962_CR79","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1075","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, Bork P (2016) The SIDER database of drugs and side effects. Nucl Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkv1075","journal-title":"Nucl Acids Res"},{"key":"962_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa891","author":"AP Davis","year":"2021","unstructured":"Davis AP et al (2021) Comparative toxicogenomics database (CTD): update 2021. Nucl Acids Res. https:\/\/doi.org\/10.1093\/nar\/gkaa891","journal-title":"Nucl Acids Res."},{"issue":"12","key":"962_CR81","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A et al (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics. 27(12):1739","journal-title":"Bioinformatics."},{"key":"962_CR82","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btr260","author":"G Csardi","year":"2006","unstructured":"Csardi G, Nepusz T (2006) The igraph software package for complex network research. Inter J Complex Syst Complex Sy. https:\/\/doi.org\/10.1093\/bioinformatics\/btr260","journal-title":"Inter J Complex Syst Complex Sy"}],"container-title":["Journal of Cheminformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-025-00962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13321-025-00962-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13321-025-00962-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T12:05:24Z","timestamp":1738670724000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcheminf.biomedcentral.com\/articles\/10.1186\/s13321-025-00962-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["962"],"URL":"https:\/\/doi.org\/10.1186\/s13321-025-00962-0","relation":{},"ISSN":["1758-2946"],"issn-type":[{"value":"1758-2946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"4 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}